DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR RENVELA
Clinical Trials for Renvela
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT00785629 | A Double Blind Randomized Placebo Trial of Maintenance of Normal Serum Phosphorus in CKD | Completed | DaVita Dialysis | N/A | The purpose of this study is to determine the ability of 3 commercially available phosphorus binders (calcium acetate, sevelamer carbonate, and lanthanum carbonate) to achieve and maintain a phosphorus level in the normal range in patients with chronic kidney disease. |
NCT00785629 | A Double Blind Randomized Placebo Trial of Maintenance of Normal Serum Phosphorus in CKD | Completed | Fresenius Medical Care North America | N/A | The purpose of this study is to determine the ability of 3 commercially available phosphorus binders (calcium acetate, sevelamer carbonate, and lanthanum carbonate) to achieve and maintain a phosphorus level in the normal range in patients with chronic kidney disease. |
NCT00785629 | A Double Blind Randomized Placebo Trial of Maintenance of Normal Serum Phosphorus in CKD | Completed | Genzyme, a Sanofi Company | N/A | The purpose of this study is to determine the ability of 3 commercially available phosphorus binders (calcium acetate, sevelamer carbonate, and lanthanum carbonate) to achieve and maintain a phosphorus level in the normal range in patients with chronic kidney disease. |
NCT00785629 | A Double Blind Randomized Placebo Trial of Maintenance of Normal Serum Phosphorus in CKD | Completed | Novartis Pharmaceuticals | N/A | The purpose of this study is to determine the ability of 3 commercially available phosphorus binders (calcium acetate, sevelamer carbonate, and lanthanum carbonate) to achieve and maintain a phosphorus level in the normal range in patients with chronic kidney disease. |
NCT00785629 | A Double Blind Randomized Placebo Trial of Maintenance of Normal Serum Phosphorus in CKD | Completed | Shire | N/A | The purpose of this study is to determine the ability of 3 commercially available phosphorus binders (calcium acetate, sevelamer carbonate, and lanthanum carbonate) to achieve and maintain a phosphorus level in the normal range in patients with chronic kidney disease. |
Trial ID | Title | Status | Sponsor | Phase | Summary |
Clinical Trial Conditions for Renvela
Condition Name
Condition MeSH
Clinical Trial Locations for Renvela
Trials by Country
Clinical Trial Progress for Renvela
Clinical Trial Phase
Clinical Trial Sponsors for Renvela
Sponsor Name